ABVC BioPharma Statistics

Total Valuation

ABVC BioPharma has a market cap or net worth of $33.48 million. The enterprise value is $36.14 million.

Market Cap	33.48M
Enterprise Value	36.14M

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

ABVC BioPharma has 16.25 million shares outstanding. The number of shares has increased by 118.45% in one year.

Current Share Class	16.25M
Shares Outstanding	16.25M
Shares Change (YoY)	+118.45%
Shares Change (QoQ)	+13.36%
Owned by Insiders (%)	28.78%
Owned by Institutions (%)	1.77%
Float	11.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	52.60
Forward PS	n/a
PB Ratio	5.58
P/TBV Ratio	6.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	71.09
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.22, with a Debt / Equity ratio of 0.36.

Current Ratio	0.22
Quick Ratio	0.03
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.95

Financial Efficiency

Return on equity (ROE) is -42.42% and return on invested capital (ROIC) is -15.21%.

Return on Equity (ROE)	-42.42%
Return on Assets (ROA)	-10.91%
Return on Invested Capital (ROIC)	-15.21%
Return on Capital Employed (ROCE)	-31.43%
Revenue Per Employee	$26,757
Profits Per Employee	-$153,198
Employee Count	19
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	-110,539
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +188.92% in the last 52 weeks. The beta is 0.19, so ABVC BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	+188.92%
50-Day Moving Average	1.35
200-Day Moving Average	0.80
Relative Strength Index (RSI)	67.49
Average Volume (20 Days)	314,459

Short Selling Information

The latest short interest is 450,565, so 2.77% of the outstanding shares have been sold short.

Short Interest	450,565
Short Previous Month	444,395
Short % of Shares Out	2.77%
Short % of Float	3.91%
Short Ratio (days to cover)	1.54

Income Statement

In the last 12 months, ABVC BioPharma had revenue of $508,384 and -$2.91 million in losses. Loss per share was -$0.22.

Revenue	508,384
Gross Profit	507,898
Operating Income	-2.56M
Pretax Income	-12.37M
Net Income	-2.91M
EBITDA	-2.52M
EBIT	-2.56M
Loss Per Share	-$0.22

Full Income Statement

Balance Sheet

The company has $217,258 in cash and $2.88 million in debt, giving a net cash position of -$2.66 million or -$0.16 per share.

Cash & Cash Equivalents	217,258
Total Debt	2.88M
Net Cash	-2.66M
Net Cash Per Share	-$0.16
Equity (Book Value)	7.96M
Book Value Per Share	0.37
Working Capital	-5.26M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-1.39M
Capital Expenditures	n/a
Free Cash Flow	-1.39M
FCF Per Share	-$0.09

Full Cash Flow Statement

Margins

Gross Margin	99.90%
Operating Margin	-503.55%
Pretax Margin	-666.05%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ABVC BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-118.45%
Shareholder Yield	-118.45%
Earnings Yield	-8.69%
FCF Yield	-4.16%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jul 25, 2023
Split Type	Reverse
Split Ratio	0.1:1

Scores

ABVC BioPharma has an Altman Z-Score of -6.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.8
Piotroski F-Score	3